Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma With Self-reported Chronic Rhinosinusitis
The Journal of Allergy and Clinical Immunology: In Practice, ISSN: 2213-2198, Vol: 8, Issue: 2, Page: 527-539.e9
2019
- 55Citations
- 188Usage
- 103Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations55
- Citation Indexes54
- 54
- CrossRef26
- Policy Citations1
- Policy Citation1
- Usage188
- Downloads185
- Abstract Views3
- Captures103
- Readers103
- 103
- Mentions1
- News Mentions1
- News1
Most Recent News
Serum Proteomic Analysis Revealed Biomarkers for Eosinophilic Chronic Rhinosinusitis with Nasal Polyps Pathophysiology
1Department of Otolaryngology-Head and Neck Surgery, the Third Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China; 2Department of Pathology, the Third Xiangya
Article Description
Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4 and IL-13 signaling, key drivers of type 2 inflammation. In the phase 3 study (NCT02414854), add-on dupilumab 200mg/300mg every 2 weeks, versus placebo, significantly reduced severe asthma exacerbations and improved pre-bronchodilator forced expiratory volume in 1 second (FEV 1 ) and quality-of-life measures in patients with uncontrolled, moderate-to-severe asthma, with greater efficacy observed in those with a high baseline type 2 phenotype. To assess the efficacy and safety of dupilumab in uncontrolled, moderate-to-severe asthma patients with or without self-reported comorbid chronic rhinosinusitis (CRS or non-CRS). Comorbid CRS was self-reported by patients using an e-diary. Annualized severe exacerbation rates, changes from baseline in pre- and post-bronchodilator FEV 1, patient-reported outcomes, type 2 biomarkers, and safety were assessed. CRS was self-reported by 382/1902 (20.1%) patients. Dupilumab 200mg/300mg reduced annualized severe exacerbation rates by 63%/61%, respectively, in patients with CRS, and by 42%/40% in patients without CRS (all P <.001 vs placebo). Dupilumab also improved lung function and patient-reported asthma control and quality of life, and suppressed type 2 biomarkers versus placebo in both subgroups. Clinical responses were rapid, with near-maximal responses observed at the earliest measured timepoints and sustained at week 52. Improvements observed in the CRS subgroup were similar to or numerically greater than those in the non-CRS subgroup. Dupilumab showed efficacy and was generally well tolerated in patients with uncontrolled, moderate-to-severe asthma with or without CRS.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2213219819306336; http://dx.doi.org/10.1016/j.jaip.2019.07.016; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85072342261&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/31351189; https://clinicaltrials.gov/ct2/show/NCT01854047; https://linkinghub.elsevier.com/retrieve/pii/S2213219819306336; https://digitalcommons.wustl.edu/open_access_pubs/8757; https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article=9756&context=open_access_pubs; https://dx.doi.org/10.1016/j.jaip.2019.07.016
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know